Immunophotonics

Immunophotonics is developing a platform based on a proprietary glycan polymer (IP-001) that enhances antigen capture and immune system activation, with an initial focus on oncology. The company's strategy involves using IP-001 in combination with standard tumor ablation techniques to convert a localized procedure into a systemic immunotherapy, potentially improving outcomes for solid tumors. Founded in 2010 and based in St. Louis, the private company is advancing its lead candidate through clinical trials while exploring platform applications to enhance other immunotherapies like checkpoint inhibitors.

Proprietary glycan polymer (IP-001) designed to stimulate antigen capture, uptake, and immune activation, functioning as an in situ vaccine platform.

Immunophotonics competes in the crowded field of cancer immunotherapy, specifically against other companies developing in situ vaccination strategies, immune adjuvants, and combination therapies to enhance antigen presentation and T-cell responses. Competitors range from large pharma with combination trials to smaller biotechs with novel platform technologies.